Arzeda company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series B | Alive

Total Raised


Last Raised

$33M | 1 yr ago

Mosaic Score

+30 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Arzeda

Arzeda leverages an advanced protein design technology to develop a portfolio of enzymes and specialty chemicals for polymers, advanced materials, and health and nutrition products.

Arzeda Headquarter Location

3421 Thorndyke Ave W

Seattle, Washington, 98199,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Arzeda

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Arzeda is included in 4 Expert Collections, including Synthetic Biology.


Synthetic Biology

305 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.


Advanced Materials

1,256 items

Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.


Biopharma Tech

838 items


Drug Discovery Tech Market Map

220 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

Arzeda Patents

Arzeda has filed 8 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Sugar substitutes
  • Acer products
patents chart

Application Date

Grant Date


Related Topics




Protein structure, Molecular biology, Bioinformatics, Transcription factors, Biotechnology


Application Date


Grant Date



Related Topics

Protein structure, Molecular biology, Bioinformatics, Transcription factors, Biotechnology



Latest Arzeda News

Academic, Industry Leaders Form OpenFold AI Research Consortium To Develop Open Source Software Tools To Understand Biological S...

Jun 30, 2022

DAVIS, CALIF.--(BUSINESS WIRE)-- A set of leading academic and industry partners are announcing the formation of OpenFold , a non-profit artificial intelligence (AI) research consortium of organizations whose goal is to develop free and open source software tools for biology and drug discovery. OpenFold is a project of the Open Molecular Software Foundation (OMSF), a non-profit organization advancing molecular sciences by building communities for open source research software development. This press release features multimedia. View the full release here: Brian Weitzner, Ph.D. Associate Director of Computational and Structural Biology at Outpace and a co-founder of OpenFold said, “In biology, structure and function are inextricably linked, so a deep understanding of structure is required to elucidate molecular mechanisms and engineer biological systems. We believe that open collaboration and access to powerful AI-powered structural biology tools will transform biotechnology and biosciences by empowering researchers and educators spanning life science companies, tech companies and academia with free access to use and extend these tools to accelerate discovery and develop life-changing technologies.” The first major research area for the consortium is to create state-of-the-art AI-based protein modeling tools which can predict molecular structures with atomic accuracy. The OpenFold consortium is modeled after pre-competitive technology industry open source consortia such as Linux and OpenAI . First consortium-released AI model to predict protein structure yielding impressive results The OpenFold founders also officially announced today the full release of its first protein structure prediction AI model developed in Dr. AlQuraishi’s laboratory, first publicly acknowledged on Twitter on June 22, 2022 . The model is based on groundbreaking work at Google DeepMind and the University of Washington’s Institute for Protein Design. The software is available under a free and open source license from The Apache Software Foundation at . Training data can be found on the Registry of Open Data on AWS . A formal preprint and publication will be forthcoming. Yih-En Andrew Ban, Ph.D., VP Computing at Arzeda and co-founder of OpenFold said, “This first OpenFold AI model is already producing highly accurate predictions of protein crystal structures as benchmarked on the Continuous Automated Model EvaluatiOn (CAMEO) , and has yielded on-average higher accuracy and faster runtimes than DeepMind’s AlphaFold2 .” An example output from OpenFold, with comparison to experimental data, is included in the figure. CAMEO is a project developed by the protein structure prediction scientific community to evaluate the accuracy and reliability of predictions. Lucas Nivon, Ph.D., CEO at Cyrus and co-founder of OpenFold, said, “The first release of the OpenFold software includes not just inference code and model parameters but full training code, a complete package that has not been released by another entity in the space. It will allow a full set of derivative models to be trained for specialized uses in drug discovery of biologics, small molecules, and other modalities.” Researchers around the world will be able to use, improve, and contribute to what the consortium founders describe as their “predictive molecular microscope.” Current and future work will extend these derivative models to integrate with other software in the field and to be more useful for protein design and biologics drug discovery specifically. Richard Bonneau, Ph.D., Executive Director at Genentech’s Prescient Design said, “OpenFold is many things to us, a code, a forum, a set of great minds to discuss our favorite topics! It has been a wonderful experience so far, and we are really excited to build out the next stages of the roadmap!” Multiple other corporate and non-profit organizations are currently joining the OpenFold consortium as full members, and the founders invite biotech, pharma, technology and other research organizations to join. The consortium is currently evaluating proposals for new AI protein projects from academic groups around the world. About OpenFold OpenFold is a non-profit artificial intelligence (AI) research consortium of academic and industry partners whose goal is to develop free and open-source software tools for biology and drug discovery, hosted as a project of the Open Molecular Software Foundation. For more information please visit: OpenFold Consortium View source version on Copyright Business Wire 2022

Arzeda Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Arzeda Rank

  • When was Arzeda founded?

    Arzeda was founded in 2007.

  • Where is Arzeda's headquarters?

    Arzeda's headquarters is located at 3421 Thorndyke Ave W, Seattle.

  • What is Arzeda's latest funding round?

    Arzeda's latest funding round is Series B.

  • How much did Arzeda raise?

    Arzeda raised a total of $53.28M.

  • Who are the investors of Arzeda?

    Investors of Arzeda include Conti Ventures, OS Fund, Bioeconomy Capital, Universal Materials Incubator, Casdin Capital and 9 more.

  • Who are Arzeda's competitors?

    Competitors of Arzeda include Biomatter Designs.

You May Also Like

Cyrus Biotechnology Logo
Cyrus Biotechnology

Cyrus Biotechnology offers advanced software tools for protein modeling and engineering to customers in Biotech, Pharma, Consumer Products, Chemicals, and Synthetic Biology. It is based in Seattle, Washington.

LabGenius Logo

LabGenius is a drug discovery company focused on the discovery of next-generation protein therapeutics. The company’s discovery platform, EVA, integrates several bleeding-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. Following discovery and characterization, LabGenius’ proprietary molecules are taken to the clinic through pharma partnerships.

Biomatter Designs Logo
Biomatter Designs

Biomatter Designs is pioneering the technologies for generative protein design at the intersection of synthetic biology and AI.

Codexis Logo

Codexis discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.